CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Option exercise Director acquired 2,778 shares (option exercise)
- 4 Option exercise Director acquired 2,778 shares (option exercise)
- 10-Q Report Quarterly Report
- 4 Option exercise Director acquired 100,000 shares (option exercise)
- 4 Option exercise 10% owner acquired 150,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 6,000 shares at $2.91 ($17,430)
- 4 Open-market buy 10% owner bought 4,000 shares at $3.29 ($13,170)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 16,400 shares at an average $3.62 ($59,379)
- 4 Open-market buy 10% owner bought 5,600 shares at an average $4.06 ($22,715)
- 4 Open-market buy 10% owner bought 1,500 shares at an average $4.24 ($6,360)
- SC 13D/A Stake Beneficial Ownership Report
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 1,340,333 shares at an average $1.52 ($2,031,863)
- 10-K Report Annual Report
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 12,500 shares at an average $5.08 ($63,554)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 3,000 shares at $5.20 ($15,605)
- 4 Open-market buy 10% owner bought 5,300 shares at an average $5.63 ($29,818)
Page 15 of 20 · 398 filings